Overview
LFMD market data
Price History
LFMD price chart
Valuation & Profitability
- P/E (TTM)
- 829.68 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.32 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.94 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 1.9% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 0.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.56 – $7.32 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $166.8M · P/B 7.09 · P/S 0.82.
Company News
HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $9Benzinga · Aug 7, 2026, 1:07 PM
B. Riley Securities Maintains Buy on LifeMD, Lowers Price Target to $8Benzinga · Aug 6, 2026, 1:58 PM
LifeMD shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 sales guidance. Also, the company issued Q3 sales guidance below estimates.Benzinga · Aug 6, 2026, 1:24 PM
BTIG Maintains Buy on LifeMD, Lowers Price Target to $9Benzinga · Aug 6, 2026, 9:28 AM
LifeMD Lowers FY2026 Sales Guidance from $220.000M-$230.000M to $205.500M-$212.500M vs $222.046M EstBenzinga · Aug 5, 2026, 8:49 PM
LifeMD Sees Q3 Sales $48.000M-$51.000M vs $58.547M EstBenzinga · Aug 5, 2026, 8:49 PM
LifeMD Q2 EPS $(0.16) Misses $(0.15) Estimate, Sales $47.300M Miss $49.152M EstimateBenzinga · Aug 5, 2026, 8:13 PM
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) InjectionGlobenewswire Inc · Jun 22, 2026, 12:15 PM
LifeMD To Launch Program For XYOSTED InjectionBenzinga · Jun 22, 2026, 12:15 PM
HC Wainwright & Co. Reiterates Buy on LifeMD, Maintains $10 Price TargetBenzinga · May 26, 2026, 4:36 PM